Abstract
Sickle cell disease is a genetic disorder associated with lifelong symptoms of anemia, vaso-oclusive crisis and organ damage. Pulmonary complications and declining lung functions are contributors to morbidity and mortality. Determination of lung functions can enable early diagnosis and institution of appropriate intervention.
The objectives were; To determine the prevalence, patterns, and the factors associated with abnormal lung functions in children and adolescents aged 6-17 years with confirmed diagnosis Sickle Cell Disease.
This was a cross sectional study done at Jaramogi Oginga Odinga Teaching and Referral Hospital in Kisumu, Kenya. A total of 138 participants were recruited. A structured data collection tool was used to collect Socio-demographics and clinical characteristics. The spirometry was done using NDD Easy-On PC spirometer and results entered into database, cleaned and analyzed for proportions, frequency, mean, range and odds ratio at 95% confidence level.
Females were 65(47%), males 73(53%), and the mean age was 10.99 years with SD of 3.15. A total of 79(57%) were from rural and fuel used was fired wood 41%. Hospital admission were 84(61%), vaso-oclusive crisis 104 (75%), acute chest syndrome 61(44%) and blood transfusions 56(40%) in the last 12 months. Prevalence of abnormal lung functions was 28 % (39), restrictive pattern 26(67%) and obstructive pattern 13(33%). Urban setting (OR 24.101 p value 0.163), being female (OR 18.911 p value 0.069), and blood transfusion (OR 11.683 p value 0.195) had high odds ratio while, stable hydroxyurea use (OR 0.525 p value 0.678) and hospital admission (OR 0.048 p value 0.121) had low odds ratio, but not statistically significant.
One third had abnormal lung function mostly restrictive followed by obstructive pattern. Residence in urban setting, being female and blood transfusion had high odds ratio, while stable hydroxyurea use and hospital admission had low odds ratio but no statistically significant.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NA
Funding Statement
No funding was received for this work
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Ethics Moi University
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data will be deposited in a public depository, currently can be obtained by request from the corresponding author
